Retatrutide
Metabolic
ABOUT
Retatrutide is an investigational triple agonist at GIP, GLP-1, and glucagon receptors. Randomized phase-II studies have examined it in defined type-2-diabetes and obesity populations.
EVIDENCE OVERVIEW
Early human findings, not yet confirmed
WHAT THIS MEANS
Potential. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Retatrutide is a single-molecule triple agonist at the GIP, GLP-1 and glucagon receptors. The glucagon-receptor component is the addition over tirzepatide and is thought to raise energy expenditure directly, in contrast to the appetite- and gastric-emptying-driven effects of the incretin arms.
PHARMACOKINETICS
Approximately six-day half-life from phase 1/2 characterisation, consistent with once-weekly subcutaneous dosing.
REVIEW
PUBLISHED PAIR RECORDS
with Tirzepatide
Overlapping incretin-receptor activityTirzepatide and investigational retatrutide both act at GIP and GLP-1 receptors. No curated direct combination study was identified. Tirzepatide labelling advises against coadministration with GLP-1 receptor agonists, so this combination warrants clinician or pharmacist review rather than self-directed stacking.
Reviewed 19 Aug 2026with Semaglutide
Overlapping GLP-1 receptor activitySemaglutide and investigational retatrutide both include GLP-1 receptor activity. No curated direct combination study was identified. This is a mechanism overlap, not proof of a specific clinical outcome; it should be reviewed with a clinician or pharmacist rather than self-directed.
Reviewed 19 Aug 2026with Survodutide
Overlapping incretin-pathway activityRetatrutide and Survodutide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Mazdutide
Overlapping incretin-pathway activityRetatrutide and Mazdutide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Cagrilintide
Overlapping incretin-pathway activityRetatrutide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Native GIP
Overlapping incretin-pathway activityRetatrutide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with MK-677
Opposing effects on glucose regulationMK-677 raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Retatrutide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Tesamorelin
Opposing effects on glucose regulationTesamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Retatrutide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with CJC-1295 with DAC
Opposing effects on glucose regulationCJC-1295 with DAC raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Retatrutide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Sermorelin
Opposing effects on glucose regulationSermorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Retatrutide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Ipamorelin
Opposing effects on glucose regulationIpamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Retatrutide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with PT-141
Additive delay of gastric emptyingBremelanotide (PT-141) labelling states that it slows gastric emptying and may reduce the rate and extent of absorption of concomitantly administered oral medicines - patients are advised to avoid it alongside oral drugs that depend on threshold concentrations, and to avoid oral naltrexone products entirely because exposure is significantly decreased. Approved GLP-1 labelling carries the same gastric-emptying caution. Scheduling Retatrutide alongside PT-141 therefore stacks two agents that independently delay gastric emptying, which matters most for any oral medicine taken in the same window. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Liraglutide
Overlapping incretin-pathway activityLiraglutide and Retatrutide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Exenatide
Overlapping incretin-pathway activityExenatide and Retatrutide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Dulaglutide
Overlapping incretin-pathway activityDulaglutide and Retatrutide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Pramlintide
Labelled caution: two agents that slow gastric emptyingPramlintide labelling states that it slows gastric emptying, that it is not recommended for patients taking other drugs that alter gastrointestinal motility, and that concomitant oral medicines whose effect depends on a threshold concentration should be taken at least 1 hour before or 2 hours after injection. Retatrutide carries its own labelled statement that it delays gastric emptying and may affect the absorption of concomitantly administered oral medicines. This is therefore not an inference from shared mechanism - each product's own labelling describes the effect the other also produces. Pramlintide additionally carries a boxed warning for severe hypoglycaemia when used with insulin, and GLP-1 labelling records increased hypoglycaemia risk in combination with insulin or an insulin secretagogue. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Teduglutide
Opposing effects on intestinal absorptionTeduglutide is a GLP-2 analogue that increases villus height and crypt depth, enlarging absorptive surface area; its labelling records a potential for increased absorption of concomitant oral medicines and advises monitoring where a drug is titrated or has a narrow therapeutic index, since the oral drug may need its dose reduced. Retatrutide works in the opposite direction on the same variable - incretin-pathway labelling and pharmacology describe delayed gastric emptying, which slows the rate at which an oral medicine reaches the small intestine. One agent is enlarging the absorptive surface while the other is changing the timing of delivery to it, so the net effect on any co-administered oral medicine is not predictable from either alone. The metabolic agent in this pair is investigational, so no labelled combination guidance exists for it. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with CJC-1295 / Ipamorelin blend
Inherited from a component of this blendCJC-1295 / Ipamorelin blend contains Ipamorelin, and the catalogue holds a curated pair record between that component and Retatrutide: Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 with DAC / Ipamorelin blend
Inherited from a component of this blendCJC-1295 with DAC / Ipamorelin blend contains CJC-1295 with DAC and Ipamorelin, and the catalogue holds a curated pair record between those components and Retatrutide: CJC-1295 with DAC (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Sermorelin / Ipamorelin blend
Inherited from a component of this blendSermorelin / Ipamorelin blend contains Sermorelin and Ipamorelin, and the catalogue holds a curated pair record between those components and Retatrutide: Sermorelin (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Kyinsu
Inherited from a component of this blendKyinsu contains Semaglutide, and the catalogue holds a curated pair record between that component and Retatrutide: Semaglutide (overlapping glp-1 receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CagriSema
Inherited from a component of this blendCagriSema contains Semaglutide and Cagrilintide, and the catalogue holds a curated pair record between those components and Retatrutide: Semaglutide (overlapping glp-1 receptor activity); Cagrilintide (overlapping incretin-pathway activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
Investigational and not approved anywhere. The published evidence is phase 2: a randomised placebo-controlled trial in obesity reported substantial dose-dependent weight reduction over 48 weeks, and a separate phase 2 trial in type 2 diabetes tested it against placebo and an active comparator. The phase 3 TRIUMPH programme - covering obesity, obstructive sleep apnoea and knee osteoarthritis - has published its rationale and design, and the sponsor has announced topline results, but those results have not yet appeared in the peer-reviewed literature. Peppy records the phase 2 findings and the existence of the phase 3 programme; the phase 3 numbers in circulation come from company announcements and are not carried here.
REPORTED EFFECTS
The phase 2 trials reported the gastrointestinal profile characteristic of this class, dose-related and most pronounced during escalation. A dysesthesia signal - abnormal skin sensation - has been described at higher doses and is the finding most worth watching as fuller data arrives. Full adverse-event profiles await peer-reviewed publication of the phase 3 results, and there is no approved label, so nothing here is label-verified.
RESEARCH LIMITATIONS
Phase-II results in selected trial populations do not establish long-term safety, suitability, or approval status for an individual. This record is not a recommendation or protocol; only the studied product and context are represented by its sources.
CURATED SOURCES · 4